Allergy and asthma proceedings最新文献

筛选
英文 中文
Real-world experience with oral on-demand treatment sebetralstat for hereditary angioedema in a retrospective case series. 实际经验口服按需治疗sebetralstat遗传性血管性水肿的回顾性病例系列。
IF 2 3区 医学
Allergy and asthma proceedings Pub Date : 2026-11-13 DOI: 10.2500/aap.2027.48.260098
Robin Lochbaum, Raphael Mohrle, Thomas K Hoffmann, Jens Greve, Janina Hahn
{"title":"Real-world experience with oral on-demand treatment sebetralstat for hereditary angioedema in a retrospective case series.","authors":"Robin Lochbaum, Raphael Mohrle, Thomas K Hoffmann, Jens Greve, Janina Hahn","doi":"10.2500/aap.2027.48.260098","DOIUrl":"https://doi.org/10.2500/aap.2027.48.260098","url":null,"abstract":"<p><strong>Background: </strong>Patients with hereditary angioedema (HAE) have unpredictable swelling attacks that can be painful and lifethreatening. Despite guidelines that recommend early on-demand treatment (ODT) for every attack, real-world adherenceremains suboptimal, partly due to treatment barriers with parenteral treatments, the only options available until 2025.</p><p><strong>Objective: </strong>The objective was to report the real-world experience with sebetralstat, the first approved oral ODT for all HAEtypes.</p><p><strong>Methods: </strong>This single-center retrospective analysis (May 2025 to February 2026) describes patient-reported reasons for switching to oral sebetralstat in 12 patients with HAE, 3 in a compassionate use program (CUP), and 9 after market authorization (October 2025), complemented by clinical outcomes and disease control in the 3 patients in CUP.</p><p><strong>Results: </strong>The cohort included nine patients with HAE due to C1-inhibitor deficiency and three with normal C1-inhibitor HAE. Eight patients previously used subcutaneous icatibant, three used intravenous C1-inhibitor concentrate, and one used both. Reasons for switching were administration-related treatment barriers (8/12 [66.7%]), improved lifestyle compatibility(6/12 [50.0%]), and enhanced treatment autonomy (5/12 [41.7%]). The three patients in CUP initiated treatment ~20 minutes after symptom onset in 13 of 14 attacks (nocturnal facial attack: time unknown). Symptom relief occurred after ~20-30 minutes. Thirteen of 14 attacks resolved completely between 30 minutes and 4 hours after symptom relief (facial attack: 6 hours). All attacks were treated with a single 300-mg dose. No adverse events or rebound attacks were documented. Angioedema Control Test scores decreased but remained greater than or equal to 10.</p><p><strong>Conclusion: </strong>This initial real-world experience shows that 8 of 12 patients switched to sebetralstat because of administration-related treatment barriers, interpreted as a greater willingness to initiate oral treatment. The three patients in CUP initiatedtreatment with oral sebetralstat early for all but one attack. These preliminary findings suggest that oral administrationmay reduce barriers associated with parenteral ODT.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding the whole patient with allergic disease: From disease mechanisms to personalized care. 全面了解过敏性疾病患者:从发病机制到个性化护理。
IF 2 3区 医学
Allergy and asthma proceedings Pub Date : 2026-11-01 DOI: 10.2500/aap.2026.47.260087
Joseph A Bellanti, Russell A Settipane
{"title":"Understanding the whole patient with allergic disease: From disease mechanisms to personalized care.","authors":"Joseph A Bellanti, Russell A Settipane","doi":"10.2500/aap.2026.47.260087","DOIUrl":"10.2500/aap.2026.47.260087","url":null,"abstract":"","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"47 6","pages":"377-379"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13739087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149284812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultraviolet irradiation and the home microbiome in childhood asthma: An exploratory environmental analysis. 紫外线照射与儿童哮喘的家庭微生物群:探索性环境分析。
IF 2 3区 医学
Allergy and asthma proceedings Pub Date : 2026-11-01 Epub Date: 2026-10-06 DOI: 10.2500/aap.2026.47.260079
Kaleb Ware, Nicholas Ollberding, Qing Duan, David Haslam, Wanda Phipatanakul, Mark Glazman, Jonathan A Bernstein
{"title":"Ultraviolet irradiation and the home microbiome in childhood asthma: An exploratory environmental analysis.","authors":"Kaleb Ware, Nicholas Ollberding, Qing Duan, David Haslam, Wanda Phipatanakul, Mark Glazman, Jonathan A Bernstein","doi":"10.2500/aap.2026.47.260079","DOIUrl":"10.2500/aap.2026.47.260079","url":null,"abstract":"<p><p><b>Background:</b> Ultraviolet (UV) filtration units installed into central heating, ventilation, and air conditioning systems have been shown to modify indoor environmental microbiomes (EM), but it remains unclear whether central UV air filtration systems as a targeted intervention alters the EM sufficiently to modify asthma outcomes. <b>Objective:</b> The objective was to investigate changes in the microbiome from dust samples collected before and after installation of a central UV filtration system in homes of children with mild-moderate persistent asthma. <b>Methods:</b> Enrolled pediatric subjects with asthma were randomized to receive UV filtration or sham devices in their heating, ventilation, and air conditioning units. Dust samples were collected from the furnace filters and each child's bedroom inflow air ducts from the first 20 homes randomized at the two largest recruiting sites at the time of device placement and at study completion (12 months), along with periodic measurements of asthma outcomes markers by using the Composite Asthma Severity Index. Microbial DNA from each paired dust sample underwent shotgun metagenomic sequencing, and taxonomic profiles were generated with MetaPhlAn 4. Associations between changes in bacterial species abundance and changes in asthma severity were assessed with Microbiome Multivariable Associations with Linear Models in R. <b>Results:</b> A total of 14 paired dust samples (7 from the UV homes and 7 from the sham homes) from inflow air ducts with sufficient quantity of dust were included for EM analysis. Within the UV filtration homes, false discovery rate adjusted q-values < 0.05 identified associations between worsening asthma severity and reduced relative abundance of common gastrointestinal commensals, such as Bacteroides and Bifidobacterium, previously linked to a reduced risk of allergic disease and asthma; no associations at this threshold were observed in the sham homes. <b>Conclusion:</b> An exploratory study of UV air filtration units installed in homes of children with asthma identified hypothesis-generating associations between bacterial species changes and asthma severity; because the study was underpowered for between-arm comparisons, these findings do not establish that UV air filtration caused the microbiome changes and should not be interpreted as confirmatory of a UV-specific effect.Clinical trial NCT02715375, <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://www.clinicaltrials.gov\">www.clinicaltrials.gov</ext-link>.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":" ","pages":"394-398"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atopic biologic use and recalled irritable bowel syndrome symptom severity: A hypothesis generating retrospective survey evaluation. 特应性生物用药与回忆性肠易激综合征症状严重程度:产生回顾性调查评价的假设。
IF 2 3区 医学
Allergy and asthma proceedings Pub Date : 2026-11-01 DOI: 10.2500/aap.2026.47.260070
Michael W Tsoulis, Marcus S Shaker
{"title":"Atopic biologic use and recalled irritable bowel syndrome symptom severity: A hypothesis generating retrospective survey evaluation.","authors":"Michael W Tsoulis, Marcus S Shaker","doi":"10.2500/aap.2026.47.260070","DOIUrl":"10.2500/aap.2026.47.260070","url":null,"abstract":"<p><p><b>Background:</b> Case reports indicate that omalizumab may be therapeutic in patients with irritable bowel syndrome (IBS), but this has not been confirmed with follow-up studies. <b>Objective:</b> The present study sought to determine if biologics used to treat atopy have any effect on recalled IBS severity. <b>Methods:</b> All patients ≥ 12 years of age with IBS and currently taking an atopic biologic were sent a questionnaire that assesses IBS severity currently and before starting their atopic biologic. The IBS Symptom Severity Score (IBS-SSS) and IBS Adequate Relief metric were used to quantify IBS severity pre- and post-atopic biologic. Bonferroni-corrected Wilcoxon signed rank tests with Hodges-Lehman estimated median differences and 95% confidence intervals (CI) compared IBS-SSS pre- and post-atopic biologic start. Subset analyses of patients taking omalizumab or dupliumab were also conducted. <b>Results:</b> Sixteen patients (12% response rate) fully responded to the questionnaire (omalizumab, n = 7; dupilumab, n = 7; mepolizumab, n = 1; tezepelumab, n = 1). The majority were women (75%) with a median (range) age of 41 years (22-71 years). The frequency of respondents who reported adequate relief of their IBS did not differ pre- and post-atopic biologic start (p = 0.688), but patients reported significantly decreased IBS-SSS post-atopic biologic start (estimated median difference 70.0 [95% CI, 20.0-122.5]; z = -2.59, p = 0.0097). One patient (6%) taking omalizumab reported complete resolution of IBS symptoms. The majority of the patients (56%) reported a decrease of at least 50 in the IBS-SSS. Although subset analyses of patients taking omalizumab or dupilumab did not show statistically significant differences pre- and post-atopic biologic start, the estimated median IBS-SSS difference pre- and post-atopic biologic start was 93.8 (95% CI, -15.5 to 201.5) and 22.0 (95% CI, -27.5 to 149.0) for omalizumab and dupilumab, respectively. <b>Conclusion:</b> The patients with IBS reported improved recalled IBS severity after starting an atopic biologic, with patients taking omalizumab reporting a larger difference. Future controlled studies are needed to confirm this finding.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"47 6","pages":"414-420"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149284693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Art and storytelling in allergy and immunology. 过敏和免疫学中的艺术和故事。
IF 2 3区 医学
Allergy and asthma proceedings Pub Date : 2026-11-01 DOI: 10.2500/aap.2026.47.260080
Alexandra E Conway, Marylee Verdi, Alastair P Huntley, Elissa M Abrams, Erin L Reigh, Marcus S Shaker
{"title":"Art and storytelling in allergy and immunology.","authors":"Alexandra E Conway, Marylee Verdi, Alastair P Huntley, Elissa M Abrams, Erin L Reigh, Marcus S Shaker","doi":"10.2500/aap.2026.47.260080","DOIUrl":"10.2500/aap.2026.47.260080","url":null,"abstract":"<p><p><b>Background:</b> Graphic medicine can provide a level of clinical connection when words fail. <b>Objective:</b> The objective was to describe the ways in which art and storytelling have contributed to the landscape of allergy and immunology communication. <b>Methods:</b> Narrative review of allergy/immunology literature that focused on art, artistry, and storytelling in allergy/immunology. <b>Results:</b> Art can provide an emotional connection that can facilitate learning and impact clinical outcomes. Across conditions treated in the allergy/immunology clinic, there is low-certainty evidence of potential improvements in clinical communication related to atopic dermatitis, asthma, and even anaphylaxis. Art can help to address challenges with patient literacy, clinician compassion, and feelings of patient and clinician isolation and stigmatization. Several artistic innovations have promoted medical education. <b>Conclusion:</b> Nonverbal communication is a powerful tool in clinical medicine. Leveraging art as a medium for storytelling and connection can serve as a tool to help deliver the right care, at the right time, every time. Graphic medicine and visual storytelling may complement traditional communication and educational approaches in allergy/immunology. Additional rigorous studies are needed to determine their effects on clinical outcomes and identify the patients and settings most likely to benefit.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"47 6","pages":"380-385"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149284713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse childhood experiences and allergic diseases: A scoping review. 不良童年经历与过敏性疾病:范围综述。
IF 2 3区 医学
Allergy and asthma proceedings Pub Date : 2026-11-01 DOI: 10.2500/aap.2026.47.260069
Marylee Verdi, Andrew A White, Michael Sun, Natalie Chapman, Mahboobeh Mahdavinia, Christopher D Codispoti, Marcus S Shaker
{"title":"Adverse childhood experiences and allergic diseases: A scoping review.","authors":"Marylee Verdi, Andrew A White, Michael Sun, Natalie Chapman, Mahboobeh Mahdavinia, Christopher D Codispoti, Marcus S Shaker","doi":"10.2500/aap.2026.47.260069","DOIUrl":"10.2500/aap.2026.47.260069","url":null,"abstract":"<p><p><b>Background:</b> One in seven individuals experience at least four adverse childhood experiences (ACE). These experiences have been associated with poor health outcomes. <b>Objectives:</b> The objective was to map the association between ACEs and asthma, food allergy, allergic rhinitis, atopic dermatitis, urticaria, and mast cell activation syndrome. <b>Methods:</b> Original research that evaluated the association between ACEs and asthma, food allergy, allergic rhinitis, atopic dermatitis, urticaria, or mast cell activation syndrome was selected and abstracted. Review articles and non-peer-reviewed literature were excluded. Sources of evidence included several medical literature databases from inception to April 3, 2026. Each article was reviewed in duplicate at title and abstract, full text, and data extraction, with conflicts resolved by consensus or independent review. Quality assessment was conducted by using a modified assessment tool. <b>Results:</b> After duplicate removal (181 articles), 357 full-text articles were evaluated, with 267 studies excluded. The full text of 90 articles was assessed for eligibility, with 31 studies excluded (1 preprint, 11 wrong outcome, 1 wrong exposure, 17 wrong study design, 1 wrong population). The studies were subject to recall bias and limitations in terms of diagnostic accuracy of the outcome. Of 59 studies selected for inclusion in the review, 57 focused primarily on asthma/lung disease, 6 variably reported on poorly described allergy outcomes, and 2 reported on atopic dermatitis. No studies were identified that explored the association between ACEs and food allergy, urticaria, or mast cell activation syndrome. There is available evidence of an association of ACEs and asthma risk with a potential dose-response effect noted, indicating the possibility of a greater risk with greater ACE exposure. <b>Conclusion:</b> An association between ACEs and asthma is suggested. More research is needed to understand the impact of ACEs on other conditions evaluated by allergist/immunologists.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"47 6","pages":"386-393"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149284687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment-refractory chronic urticaria with neutrophilia and elevated inflammatory markers. 难治性慢性荨麻疹伴中性粒细胞增多和炎症标志物升高。
IF 2 3区 医学
Allergy and asthma proceedings Pub Date : 2026-11-01 DOI: 10.2500/aap.2026.47.260065
Darshan M Sivaloganathan, Rachel M Smith, Sarbjit S Saini
{"title":"Treatment-refractory chronic urticaria with neutrophilia and elevated inflammatory markers.","authors":"Darshan M Sivaloganathan, Rachel M Smith, Sarbjit S Saini","doi":"10.2500/aap.2026.47.260065","DOIUrl":"10.2500/aap.2026.47.260065","url":null,"abstract":"<p><p>Chronic spontaneous urticaria is commonly responsive to high-dose antihistamines, anti-IgE therapy, and cyclosporine; however, a subset of patients have persistent symptoms despite guideline-directed treatment. We present a case of long-standing, treatment-refractory urticaria in a 38-year-old man with persistent neutrophilia and elevated inflammatory markers. The clinical presentation prompted consideration of chronic spontaneous urticaria mimics, including urticarial vasculitis, autoimmune disease, hematologic disease, and autoinflammatory syndromes. Further evaluation included skin biopsy, expanded laboratory testing, and additional targeted investigations. This case highlights the importance of broadening the differential diagnosis in patients with chronic urticaria that is refractory to standard therapy, particularly when systemic inflammatory features are present.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"47 6","pages":"438-442"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149284837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical and laboratory factors associated with follow-up oral food challenge outcomes in cow's milk allergy. 临床和实验室因素与牛奶过敏的后续口服食物挑战结果相关。
IF 2 3区 医学
Allergy and asthma proceedings Pub Date : 2026-11-01 DOI: 10.2500/aap.2026.47.260064
Taha Y Akin, Yusuf Z Varli, Nagihan Iskender, Nefise N Uluc, Ismail Ozanli, Mebrure Yazici, Dondu C Kaval, Mehmet S Erkan, Muhammet T Demirci, Sibel Balci, Mujde T Cogurlu, Isil Eser Simsek, Metin Aydogan
{"title":"Clinical and laboratory factors associated with follow-up oral food challenge outcomes in cow's milk allergy.","authors":"Taha Y Akin, Yusuf Z Varli, Nagihan Iskender, Nefise N Uluc, Ismail Ozanli, Mebrure Yazici, Dondu C Kaval, Mehmet S Erkan, Muhammet T Demirci, Sibel Balci, Mujde T Cogurlu, Isil Eser Simsek, Metin Aydogan","doi":"10.2500/aap.2026.47.260064","DOIUrl":"10.2500/aap.2026.47.260064","url":null,"abstract":"<p><p><b>Background:</b> Reliable predictors that link first oral food challenge (OFC) responses to the outcomes of follow-up OFCs in children with food allergies are still lacking. <b>Objective:</b> To identify clinical and laboratory factors associated with follow-up OFC outcomes in preschool children with cow's milk allergy after a positive first challenge result. <b>Methods:</b> This retrospective study included 85 preschool children with cow's milk allergy who had a positive first OFC outcome and subsequently underwent follow-up OFCs. Demographic, clinical, and laboratory data were analyzed to identify factors associated with positive follow-up OFC outcomes. <b>Results:</b> Older age at the first OFC, anaphylaxis during the first OFC, pre-first OFC casein immunoglobulin E (IgE) level ≥ 3.71 kUA/L, pre-first OFC cow's milk IgE level ≥ 14 kUA/L, and larger cow's milk skin-prick test (SPT) results were associated with positive follow-up OFC outcomes. A pre-first OFC casein specific IgE (sIgE) level ≥ 3.71 kUA/L remained independently associated with follow-up OFC positivity after multivariable adjustment. In univariable analyses, reactions that occurred after completion of the full-dose protocol during the first OFC were associated with lower follow-up OFC positivity. The combination of a pre-first OFC casein IgE level < 3.71 kUA/L and a reaction after completion of the full-dose protocol during the first OFC was associated with a 92.9% negative predictive value for follow-up OFC outcomes. <b>Conclusion:</b> Clinical and laboratory markers during the first OFC may be related to follow-up OFC outcomes in children with cow's milk allergy. Higher pre-first OFC casein and cow's milk IgE levels and anaphylaxis during the first OFC were associated with follow-up OFC positivity. Lower pre-first OFC casein IgE levels, with reactions after completing the full-dose protocol, were linked to lower follow-up OFC positivity rates.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"47 6","pages":"429-437"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149284653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation of serum 25-Hydroxyvitamin D levels with total IgE and peripheral blood eosinophil counts in patients with atopic dermatitis. 特应性皮炎患者血清25-羟基维生素D水平与总IgE和外周血嗜酸性粒细胞计数的相关性
IF 2 3区 医学
Allergy and asthma proceedings Pub Date : 2026-11-01 DOI: 10.2500/aap.2026.47.260066
Yuan Liu, Lu Xue, Huiping Wang
{"title":"Correlation of serum 25-Hydroxyvitamin D levels with total IgE and peripheral blood eosinophil counts in patients with atopic dermatitis.","authors":"Yuan Liu, Lu Xue, Huiping Wang","doi":"10.2500/aap.2026.47.260066","DOIUrl":"10.2500/aap.2026.47.260066","url":null,"abstract":"<p><p><b>Background:</b> This study was conducted to investigate the correlations and independent associations between serum 25-hydroxyvitamin D (25[OH]D) levels and total immunoglobulin E (IgE) values as well as peripheral blood eosinophil (EOS) counts in adults with atopic dermatitis (AD). <b>Methods:</b> This single-center cross-sectional study included 148 adults with AD. Data on age, sex, body mass index, disease duration, season, sensitization status, and allergic comorbidities were collected. Serum 25(OH)D values, total IgE levels, and EOS counts were measured, and the Dermatology Life Quality Index (DLQI), Eczema Area and Severity Index (EASI), and SCORing Atopic Dermatitis (SCORAD) scores were assessed. EOS counts and total IgE levels were designated as coprimary end points, and Bonferroni-adjusted p-values were calculated to control for multiple testing. <b>Results:</b> The median serum 25(OH)D level was 19 ng/mL, and vitamin D deficiency or insufficiency was common. Serum 25(OH)D was inversely correlated with EOS counts (r = -0.502, raw p < 0.001; p < 0.002, Bonferroni adjusted) and total IgE levels (r = -0.492, raw p < 0.001; p < 0.002, Bonferroni-adjusted). Both associations remained statistically significant in the fully adjusted regression models after Bonferroni adjustment. Higher vitamin D categories showed decreasing trends in EOS counts and total IgE levels (both raw p-values for trend < 0.001; both Bonferroni-adjusted p-values for trend < 0.002). However, no statistically significant differences in EASI and SCORAD scores were detected among vitamin D categories (p = 0.160 and p = 0.080, respectively). <b>Conclusion:</b> In adults with AD, serum 25(OH)D was inversely associated with peripheral blood EOS counts and total IgE levels, whereas no statistically significant differences in the clinical severity scores were detected across vitamin D categories. Analysis of these findings suggests an association with systemic inflammatory markers rather than established clinical utility.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"47 6","pages":"e127-e139"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149284656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Residual exacerbation phenotypes during anti-IL-5/IL-5R (IL-5 receptor) therapy in severe eosinophilic asthma. 抗IL-5/IL-5R (IL-5受体)治疗严重嗜酸性哮喘期间的残留加重表型。
IF 2 3区 医学
Allergy and asthma proceedings Pub Date : 2026-11-01 DOI: 10.2500/aap.2026.47.260075
Hatice Celik Tuglu, Kurtulus Aksu
{"title":"Residual exacerbation phenotypes during anti-IL-5/IL-5R (IL-5 receptor) therapy in severe eosinophilic asthma.","authors":"Hatice Celik Tuglu, Kurtulus Aksu","doi":"10.2500/aap.2026.47.260075","DOIUrl":"10.2500/aap.2026.47.260075","url":null,"abstract":"<p><p><b>Background:</b> Although anti-interleukin (IL) 5/IL-5 receptor therapies effectively reduce the exacerbation burden in severe eosinophilic asthma, some patients continue to experience residual exacerbations despite biologic treatment. The inflammatory characteristics of these exacerbations remain insufficiently defined. <b>Objective:</b> The objective was to evaluate the clinical and inflammatory phenotypes of asthma exacerbations that occur during mepolizumab or benralizumab therapy in patients with severe eosinophilic asthma. <b>Methods:</b> This retrospective real-world study included patients with severe eosinophilic asthma who experienced exacerbations despite anti-IL-5/IL-5 receptor therapy. Exacerbations were classified as eosinophilic, neutrophilic, paucigranulocytic, or mixed granulocytic according to peripheral blood eosinophil and neutrophil counts. Clinical characteristics, inflammatory phenotypes, pulmonary function parameters, eosinophil levels, and annual exacerbation frequencies were evaluated. <b>Results:</b> Forty-two patients who experienced 63 exacerbations during biologic therapy were included. The median age was 48.5 years, and 66.7% of the patients were women. The annual exacerbation frequency significantly decreased after biologic treatment initiation in both treatment groups. Among the patients who completed the first treatment year, 66.7% of the patients treated with benralizumab and 55.1% of the patients treated with mepolizumab remained exacerbation-free. No significant differences were observed between biologic agents with regard to infectious exacerbation frequency or inflammatory exacerbation phenotypes. Paucigranulocytic exacerbations represented the most common phenotype in both treatment groups, whereas mixed granulocytic exacerbations were rare. Pulmonary function parameters and eosinophil levels during exacerbations were comparable between the biologic agents. <b>Conclusion:</b> Residual exacerbations that occurred during anti-IL-5/IL-5 receptor therapy demonstrated heterogeneous inflammatory phenotypes rather than a uniformly eosinophilic pattern. The predominance of paucigranulocytic exacerbations suggests that mechanisms beyond persistent eosinophilic inflammation may contribute to residual exacerbations during biologic therapy in severe eosinophilic asthma.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"47 6","pages":"399-404"},"PeriodicalIF":2.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149284709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书